Compounds > lapatinib
Page last updated: 2024-09-05

lapatinib and verapamil

lapatinib has been researched along with verapamil in 7 studies

Compound Research Comparison

Studies
(lapatinib)		Trials
(lapatinib)		Recent Studies (post-2010)
(lapatinib)		Studies
(verapamil)		Trials
(verapamil)		Recent Studies (post-2010) (verapamil)
1,9193051,44217,6211,5272,067

Protein Interaction Comparison

ProteinTaxonomylapatinib (IC50)verapamil (IC50)
Solute carrier family 22 member 1 Homo sapiens (human)6.8
Voltage-dependent L-type calcium channel subunit alpha-1FHomo sapiens (human)0.2
5-hydroxytryptamine receptor 4Cavia porcellus (domestic guinea pig)0.297
ATP-dependent translocase ABCB1Mus musculus (house mouse)2
ATP-dependent translocase ABCB1Homo sapiens (human)2.2346
Cytochrome P450 3A4Homo sapiens (human)3.8008
Alpha-2A adrenergic receptorHomo sapiens (human)0.579
5-hydroxytryptamine receptor 1ARattus norvegicus (Norway rat)3.02
ATP-dependent translocase ABCB1Mus musculus (house mouse)10
Catechol O-methyltransferaseHomo sapiens (human)0.2
Potassium voltage-gated channel subfamily A member 3Homo sapiens (human)8
Histamine H2 receptorHomo sapiens (human)2.59
5-hydroxytryptamine receptor 2AHomo sapiens (human)0.442
5-hydroxytryptamine receptor 2CHomo sapiens (human)0.297
5-hydroxytryptamine receptor 1BRattus norvegicus (Norway rat)3.02
Sodium-dependent serotonin transporterHomo sapiens (human)0.24
Multidrug resistance-associated protein 1 Homo sapiens (human)5.598
D(3) dopamine receptorHomo sapiens (human)0.186
5-hydroxytryptamine receptor 2BHomo sapiens (human)0.165
5-hydroxytryptamine receptor 7Cavia porcellus (domestic guinea pig)6.8
Voltage-dependent L-type calcium channel subunit alpha-1D Homo sapiens (human)0.2
Potassium voltage-gated channel subfamily H member 2Homo sapiens (human)0.3945
Voltage-dependent L-type calcium channel subunit alpha-1SHomo sapiens (human)0.2
Voltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)0.175
Broad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)1.1934

Research

Studies (7)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's6 (85.71)24.3611
2020's1 (14.29)2.80

Authors

AuthorsStudies
Afshari, CA; Eschenberg, M; Hamadeh, HK; Lee, PH; Lightfoot-Dunn, R; Morgan, RE; Qualls, CW; Ramachandran, B; Trauner, M; van Staden, CJ1
Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V1
Cantin, LD; Chen, H; Kenna, JG; Noeske, T; Stahl, S; Walker, CL; Warner, DJ1
Davis, MI; Khan, J; Li, SQ; Patel, PR; Shen, M; Sun, H; Thomas, CJ1
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K1
Basetti, V; Keesara, M; Maiti, P; Mansour, TS; Moghudula, AG; Pallepati, RR; Potluri, V1
Cai, Z; Ghaleb, H; Huang, W; Jiang, Y; Liu, Y; Qian, H; Qiu, Q; Shi, W; Yin, Z; Zhang, P; Zhou, J; Zou, F1

Reviews

1 review(s) available for lapatinib and verapamil

ArticleYear
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
    Drug discovery today, 2016, Volume: 21, Issue:4

    Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk

2016

Other Studies

6 other study(ies) available for lapatinib and verapamil

ArticleYear
Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
    Toxicological sciences : an official journal of the Society of Toxicology, 2010, Volume: 118, Issue:2

    Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Assay; Biological Transport; Cell Line; Cell Membrane; Chemical and Drug Induced Liver Injury; Cytoplasmic Vesicles; Drug Evaluation, Preclinical; Humans; Liver; Rats; Reproducibility of Results; Spodoptera; Transfection; Xenobiotics

2010
FDA-approved drug labeling for the study of drug-induced liver injury.
    Drug discovery today, 2011, Volume: 16, Issue:15-16

    Topics: Animals; Benchmarking; Biomarkers, Pharmacological; Chemical and Drug Induced Liver Injury; Drug Design; Drug Labeling; Drug-Related Side Effects and Adverse Reactions; Humans; Pharmaceutical Preparations; Reproducibility of Results; United States; United States Food and Drug Administration

2011
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.
    Drug metabolism and disposition: the biological fate of chemicals, 2012, Volume: 40, Issue:12

    Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Bile Acids and Salts; Cell Line; Chemical and Drug Induced Liver Injury; Humans; Quantitative Structure-Activity Relationship

2012
Identification of potent Yes1 kinase inhibitors using a library screening approach.
    Bioorganic & medicinal chemistry letters, 2013, Aug-01, Volume: 23, Issue:15

    Topics: Binding Sites; Cell Line; Cell Survival; Drug Design; Humans; Hydrogen Bonding; Molecular Docking Simulation; Protein Kinase Inhibitors; Protein Structure, Tertiary; Proto-Oncogene Proteins c-yes; Small Molecule Libraries; Structure-Activity Relationship

2013
Lead generation of 1,2-dithiolanes as exon 19 and exon 21 mutant EGFR tyrosine kinase inhibitors.
    Bioorganic & medicinal chemistry letters, 2019, 06-15, Volume: 29, Issue:12

    Topics: Exons; Humans; Mutation; Protein Kinase Inhibitors; Thioctic Acid

2019
Exploration of novel phthalazinone derivatives as potential efflux transporter inhibitors for reversing multidrug resistance and improving the oral absorption of paclitaxel.
    European journal of medicinal chemistry, 2022, Apr-05, Volume: 233

    Topics: ATP Binding Cassette Transporter, Subfamily G, Member 2; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Humans; Neoplasm Proteins; Neoplasms; Paclitaxel

2022